Current Status and Expectation of the Biopharmaceutical Industry in China
- VernacularTitle:我国生物医药企业的现状与展望
- Author:
Wei LIU
;
Chao LI
;
- Publication Type:Journal Article
- Keywords:
Biopharmaceutical industry Current Status Expectation
- From:
China Biotechnology
2006;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Biotech is currently the fastest growing sector in drug industry. Globally biotech products generated revenues of $55bn in 2004, in a total drug market worth $550bn. The USA is the primary market of biotech products, being the source of approximately half of sales in 2004. About 55% of biopharmaceuticals’ sales in 2004 came from the five leading products (Erythropoietin,Interferon,Human insulin,G-CSF,Rituximab).Great progress has been made in the biotech market of China over the last few years. About 60%~70% of recombinant protein biopharmaceuticals are expressed in mammalian cells in USA and EU, while most recombinant protein biopharmaceuticals are expressed in E.coli in China. Most biopharmaceuticals expressed in mammalian cell can’t be manufactured in China. The biotech industry comprise numerous, mostly small organizations. These organizations typically employ less than 100 people. Most biotech companies have never brought a product to market before they disappear. Therefore, it is very important for biotech companies to make an appropriate development strategy.
